Results 51 to 60 of about 6,382 (183)
Neoplasia: An International Journal for Oncology Research, 2021 Burkitt's lymphoma (BL) is a highly aggressive form of B-cell non-Hodgkin's lymphoma. The clinical outcome in children with BL has improved over the last years but the prognosis for adults is still poor, highlighting the need for novel treatment ...
Annkathrin Koch +5 more
doaj +1 more source
Frontiers in Cell and Developmental BiologyIntroductionMixed Lineage Kinase Domain-Like Protein (MLKL), as the executor of necroptosis and a critical factor in the inflammation, has been shown to be associated with the progression of hemorrhagic stroke.
Yi Wang +12 more
doaj +1 more source
Nature Communications, 2021 Mixed Lineage Kinase Domain-Like (MLKL) pseudokinase is phosphorylated by RIPK3 kinase prior to cell death by necroptosis. Here, the authors use monobodies that bind to the MLKL pseudokinase domain as tools, which allowed them to determine the crystal ...
Sarah E. Garnish +18 more
doaj +1 more source
Journal of Pharmacological Sciences, 2023 Accumulating evidence suggests that necroptosis of cardiomyocytes contributes to cardiovascular diseases. Lethal disruption of the plasma membrane in necroptosis is induced by oligomers of mixed lineage kinase domain-like (MLKL) that is translocated to ...
Shoya Ino +12 more
doaj +1 more source
A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer. [PDF]
, 2015 Serous Ovarian Cancers (SOC) are frequently resistant to programmed cell death. However, here we describe that these programmed death-resistant cells are nonetheless sensitive to agents that modulate autophagy.
Bartakova, Alena +10 more
core +2 more sources
Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma. [PDF]
, 2014 Ovarian cancer patients are typically treated with carboplatin and paclitaxel, but suffer a high rate of relapse with recalcitrant disease. This challenge has fostered the development of novel approaches to treatment, including antagonists of the ...
Axelrod, J +10 more
core +2 more sources
Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes [PDF]
, 2018 Cancer immunotherapy can induce durable antitumor responses. However, many patients poorly respond to such therapies. Here we describe a generic antitumor therapy that is based on the intratumor delivery of mRNA that codes for the necroptosis executioner
De Koker, Stefaan +8 more
core +3 more sources
NEMO regulates a cell death switch in TNF signaling by inhibiting recruitment of RIPK3 to the cell death-inducing complex II [PDF]
, 2016 Incontinentia Pigmenti (IP) is a rare X-linked disease characterized by early male lethality and multiple abnormalities in heterozygous females. IP is caused by NF-κB essential modulator (NEMO) mutations.
Draber, P +4 more
core +1 more source
Macrophage Extracellular Traps in Immunity and Cancer
Advanced Science, EarlyView.As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li +5 more
wiley +1 more source
Viral MLKL Homologs Subvert Necroptotic Cell Death by Sequestering Cellular RIPK3
Cell Reports, 2019 Summary: Necroptotic cell death has been implicated in many human pathologies and is thought to have evolved as an innate immunity mechanism. The pathway relies on two key effectors: the kinase receptor-interacting protein kinase 3 (RIPK3) and the ...
Emma J. Petrie +18 more
doaj +1 more source